Clinical Trial

PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA)

Study acronym: PRIMA
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The aim of this study is to evaluate the efficacy and safety of PARP Inhibition and programmed cell death protein-1 (PD-1) blockade immunotherapy with concurrent stereotactic body radiotherapy (SBRT) for metastatic or advanced bone and soft tissue sarcoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-10-03.
Trial Details
NCT Number NCT06074692
Lead Sponsor Ruijin Hospital
Conditions Sarcoma, Sarcoma,Soft Tissue, Sarcoma of Bone
Enrollment 86 participants
Start Date 2023-06-01
Primary Completion 2026-08-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2023-10-31